A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Place...

Update Il y a 4 ans
Reference: EUCTR2005-004749-32

A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapy

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of this study is to demonstrate an improvement in PFS in the combination of ZACTIMA with docetaxel compared with docetaxel plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy


Inclusion criteria

  • non-small cell lung cancer